KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $68.49 $68.49 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $68.49 $68.49
52 weeks $21.65 $73.02

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Jul 02, 2019 $53.71 $55.65 $53.39 $55.58 1 087 904
Jul 01, 2019 $53.32 $54.41 $51.55 $53.93 1 324 704
Jun 28, 2019 $54.44 $54.58 $51.69 $52.60 3 056 148
Jun 27, 2019 $54.27 $55.19 $53.30 $53.97 1 179 799
Jun 26, 2019 $58.30 $58.74 $53.78 $54.10 6 086 895
Jun 25, 2019 $63.56 $64.94 $62.27 $62.43 922 081
Jun 24, 2019 $63.07 $64.89 $62.74 $63.29 1 265 178
Jun 21, 2019 $59.05 $63.05 $58.01 $63.00 1 867 532
Jun 20, 2019 $59.55 $59.99 $58.43 $59.38 971 437
Jun 19, 2019 $56.46 $58.72 $55.72 $58.55 876 535
Jun 18, 2019 $54.80 $57.29 $54.25 $56.30 1 381 238
Jun 17, 2019 $54.55 $56.04 $53.52 $54.24 1 330 360
Jun 14, 2019 $55.00 $57.74 $51.30 $53.98 3 009 284
Jun 13, 2019 $54.92 $57.76 $54.91 $57.52 1 336 303
Jun 12, 2019 $55.30 $55.89 $53.69 $54.82 987 549
Jun 11, 2019 $57.90 $57.95 $55.54 $55.81 1 309 553
Jun 10, 2019 $60.15 $60.95 $57.00 $57.24 871 378
Jun 07, 2019 $59.62 $60.37 $59.16 $59.97 370 165
Jun 06, 2019 $59.95 $60.22 $58.27 $59.27 578 808
Jun 05, 2019 $60.11 $60.25 $58.22 $60.08 723 388
Jun 04, 2019 $58.95 $60.14 $58.74 $59.83 1 324 542
Jun 03, 2019 $61.64 $62.04 $57.81 $58.46 880 438
May 31, 2019 $61.00 $61.90 $60.30 $60.78 642 934
May 30, 2019 $61.68 $63.00 $61.57 $62.09 580 874
May 29, 2019 $60.68 $61.89 $59.60 $61.19 713 996
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT